Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]

Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, CEO Dr Raza Bokhari joined Matt Miller from Bloomberg World for a live interview on February 10, 2026. ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Insights - The company is developing Teverelix® as a leading product for advanced prostate cancer patients with high cardiovascular risk and as a first-in-class treatment for Acute Urinary Retention Relapse prevention, representing a combined market opportunity of approximately US$6 billion [1][20]. Clinical Development - The Phase 2b study is an open-label trial enrolling 40 men with advanced prostate cancer, with a total treatment duration of approximately 22 weeks [2]. - The primary endpoint is to confirm medical castration by Day 29 with sustained suppression through Day 155, targeting a probability exceeding 90% [2][9]. Mechanism of Action - Teverelix is a long-acting injectable GnRH antagonist that provides immediate receptor antagonism, allowing for rapid suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and downstream sex hormones without an initial testosterone surge [4][21]. - This mechanism is particularly relevant for patients with advanced prostate cancer and elevated cardiovascular risk, as GnRH agonists may contribute to adverse cardiovascular outcomes [5][6]. Target Patient Population - Teverelix is specifically developed for advanced prostate cancer patients with objectively defined cardiovascular risk, including those with recent major adverse cardiovascular events (MACE) or severe subclinical atherosclerosis [7]. - Approximately 300,000 to 500,000 men in the U.S. are living with advanced prostate cancer, representing an estimated annual market opportunity exceeding US$4 billion [7]. Regulatory Strategy - The company has received FDA clearance to initiate the Phase 2b study and has aligned on a development indication focused on hormone therapy for advanced prostate cancer patients with increased cardiovascular risk [10][23]. - A clear Phase 3 framework is defined to evaluate sustained castration efficacy alongside cardiovascular outcomes, which may establish Teverelix as a new therapeutic backbone for patients where cardiovascular safety is critical [11][10]. Strategic Partnerships - The company is well-positioned for strategic partnership discussions, particularly with organizations seeking differentiated late-stage oncology assets supported by a clear regulatory and labeling strategy [12]. - The development strategy includes advancing select programs through Phase 2 proof-of-concept and pursuing licensing or strategic partnerships for late-stage development and commercialization [13]. Additional Programs - Medicus is also advancing SkinJect™, a proprietary dissolvable microneedle array platform for the non-invasive treatment of basal cell carcinoma, with topline decision-grade data expected in Q1 2026 [14][27].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Insights - The amendment to the license agreement reduces the royalty rate on Teverelix® from approximately 4% to 2%, while maintaining global rights and intellectual property control [1][2] - Teverelix® is being developed as a first-in-class product for Acute Urinary Retention relapse prevention and as a best-in-class treatment for prostate cancer patients with high cardiovascular risk, representing a potential market opportunity of around US$6 billion [1][3] License Agreement Details - The amended agreement clarifies the royalty term on a country-by-country basis and does not change the scope of the license or the underlying intellectual property [2] - Medicus retains exclusive worldwide rights to develop, manufacture, and commercialize Teverelix, including the ability to grant sublicenses, which supports flexible global partnering strategies [3][4] Economic Impact - The reduced royalty burden is expected to enhance Teverelix's attractiveness for future partnerships, particularly for late-stage development and commercialization [3] - The amendment reflects scientific progress and intellectual property expansion achieved by the Antev team, aligning the parties under a simplified economic framework [5] Development Strategy - Medicus aims to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships for late-stage development and commercialization [10] - The company is focused on assembling decision-grade clinical and regulatory data packages to support its partnering-focused model [10] Clinical Development of Teverelix - Teverelix is a long-acting injectable GnRH antagonist that suppresses sex hormone production without an initial surge, potentially reducing cardiovascular risks for patients with existing conditions [7][18] - Previous studies have shown Teverelix to be well tolerated, with significant testosterone suppression achieved in clinical trials [19][20] SkinJect™ Program - Medicus is advancing its SkinJect™ program, a proprietary dissolvable microneedle array platform for treating basal cell carcinoma, with Phase 2 data expected in early 2026 [11][24] - The company has received regulatory approvals in the UK to expand its ongoing Phase 2 clinical study for SkinJect™ [23]

Core Insights - Medicus Pharma Ltd. is set to celebrate its one-year anniversary as a Nasdaq-listed company by ringing the Nasdaq Opening Bell on January 22, 2026, highlighting its focus on disciplined execution and clinical development [1][4] Company Overview - Medicus Pharma Ltd. is a precision-guided biotech/life sciences company dedicated to advancing clinical development programs for novel therapeutics [5] - The company operates across multiple countries on three continents [5] Clinical Pipeline - The current pipeline includes SkinJect, a localized immunogenic precision therapy for basal cell carcinoma, targeting a market opportunity estimated at $2 billion, and Teverelix, a next-generation GnRH antagonist for advanced prostate cancer patients, representing a combined market opportunity of approximately $6 billion [3][6] Recent Developments - The SkinJect program is nearing database lock and clinical data readout, which may lead to potential partnering opportunities [4][16] - Medicus has completed enrollment of 90 patients in the Phase 2 clinical study (SKNJCT-003) for SkinJect, with topline results expected in Q1 2026 [16] - The company has received regulatory approvals in the UK to expand the ongoing Phase 2 study for SkinJect [15] Collaborations and Partnerships - In August 2025, Medicus entered a non-binding memorandum of understanding with Helix Nanotechnologies to explore mutual interests in mRNA platform development [7][8] - The company acquired Antev, a UK-based biotech firm, to develop Teverelix, which is designed to directly suppress sex hormone production without an initial testosterone surge, potentially reducing cardiovascular risks [9][10] Regulatory Milestones - The FDA has provided guidance on the proposed Phase 3 trial design for Teverelix, supporting its development for advanced prostate cancer patients with increased cardiovascular risk [12] - The FDA approved the Phase 2b study design for Teverelix in advanced prostate cancer and acute urinary retention relapse, covering 40 and 390 patients respectively [13][14] Future Plans - Medicus plans to collaborate with Reliant AI Inc. to develop an AI-driven clinical data analytics platform to enhance clinical development efficiency [17][18]

Company Overview - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is a forward-looking company that adopts technology enthusiastically to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Medicus Pharma Ltd. has announced that its abstract on Teverelix has been accepted for presentation at the AACE Annual Meeting 2026, highlighting the company's focus on advancing clinical development programs for innovative therapeutics [1][2] Group 1: Teverelix Clinical Data - The accepted abstract titled "Evaluation of Teverelix, a Long-Acting GnRH Antagonist" presents results from two Phase 1 studies involving 48 healthy premenopausal women, assessing pharmacokinetics, pharmacodynamics, bone turnover, and safety [2] - Key findings indicate rapid and reversible hormone suppression with stable bone markers, demonstrating the potential of Teverelix in women's health, particularly for conditions like endometriosis affecting approximately 10% of women of reproductive age [3][7] - The studies showed that Teverelix achieved dose-dependent estradiol suppression, with levels reaching the clinically relevant Barbieri window (30–50 pg/mL), and sustained hormone suppression lasting up to two to three weeks post-injection [7] Group 2: Mechanism and Safety Profile - Teverelix operates as a long-acting injectable GnRH antagonist, providing immediate receptor antagonism and rapid suppression of LH, FSH, and downstream sex hormones without an initial surge [4][16] - The drug has not shown significant cardiovascular safety signals in prior studies, which is particularly relevant for advanced prostate cancer patients with elevated cardiovascular risk [5] Group 3: Development Strategy - Medicus aims to advance select programs through Phase 2 proof-of-concept studies and pursue strategic partnerships for late-stage development and commercialization [8] - The company is also advancing its SkinJect™ program for non-invasive treatment of basal cell carcinoma, with topline data expected in Q1 2026 [9][22] Group 4: Regulatory and Strategic Collaborations - Medicus has received regulatory approvals in the UK for expanding its Phase 2 study evaluating Doxorubicin Microneedle Array for basal cell carcinoma [21] - The company has entered a non-binding memorandum of understanding with Helix Nanotechnologies to explore collaboration on mRNA platform development [13]